Literature DB >> 11903928

The glioma-associated gangliosides 3'-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains.

K M Hedberg1, R Mahesparan, T A Read, B B Tysnes, F Thorsen, T Visted, R Bjerkvig, P Fredman.   

Abstract

This work describes the in vivo expression and distribution of glioma-associated gangliosides (GD3, GM2, 3'-isoLM1) in a novel human brain tumour nude rat xenograft model. In this model, the tumours, which are established directly from human glioblastoma biopsies, show extensive infiltrative growth within the rat brain. This model therefore provides an opportunity to study ganglioside expression not only within the macroscopic tumour, but also in brain areas with tumour cell infiltration. The ganglioside expression was studied by confocal microscopy of immunostained brain sections using antiganglioside monoclonal antibodies. Xenografts from four human glioblastoma multiformes were established in rats and the brains removed after 3-4 months. Ganglioside GD3 was expressed in the tumour parenchyma while ganglioside 3'-isoLM1 was more abundantly expressed in the periphery of the tumour associated with areas of tumour cell invasion. GM2 expression was only seen in one tumour, where it was located within the main tumour mass. Double staining with a pan antihuman monoclonal antibody (3B4) and the antiganglioside monoclonal antibodies confirmed that the ganglioside expression was associated with tumour cells. This work supports the concept of different biological roles for individual gangliosides and indicates that antibodies or ligands directed against GD3 and 3'-isoLM1 might be complementary when applied in the treatment of human glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11903928     DOI: 10.1046/j.1365-2990.2001.00353.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  2 in total

1.  Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.

Authors:  Hailan Piao; Chien-Tsun Kuan; Vidya Chandramohan; Stephen T Keir; Charles N Pegram; Xuhui Bao; Jan-Eric Månsson; Ira H Pastan; Darell D Bigner
Journal:  MAbs       Date:  2013-07-25       Impact factor: 5.857

Review 2.  Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.

Authors:  Margarita Bartish; Sonia V Del Rincón; Christopher E Rudd; H Uri Saragovi
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.